{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"25.9","upperLimit":"71.5","value":"45.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"80"}],"units":"Participants"}],"description":"Duration of HR was defined as the duration from documentation of HR to the time of relapse. HR was defined as the blood counts required for CR as normal CBC as exhibited by: Neutrophils \\>= 1.5 x 10\\^9/L, Platelets \\>= 100 x 10\\^9/L, and hemoglobin \\>= 11.0 g/dL without transfusions or growth factors for at least 4 weeks.\n\nDuration of HR was censored on the date of the last hematologic assessment for participants who have no documented relapse based on blood count prior to data cutoff, dropout, or initiation of alternative anticancer therapy.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received intravenous infusion of moxetumomab pasudotox 40 µg/kg on Days 1, 3, and 5 of each 28-day cycle for up to 6 cycles, until documentation of complete response, progressive disease, initiation of alternate therapy, or unacceptable toxicity.","id":"OG000","title":"Moxetumomab Pasudotox 40 µg/kg"}],"paramType":"MEDIAN","populationDescription":"The ITT population included participants who entered into the study and treated with moxetumomab pasudotox. Duration of HR was evaluated for participants who achieved HR.","reportingStatus":"POSTED","timeFrame":"Prior to each treatment cycle, EOT (up to 24 weeks), monthly from the EOT assessment until the Day 181 assessment (only for CBC), at follow-up visits every 3 months for the next 24 months, and every 6 months thereafter (approximately 6 years)","title":"Duration of Hematologic Remission","type":"SECONDARY","unitOfMeasure":"Months"}